Adenosine Kinase (ADK) Antibody

819€ (1 ml)
Por favor contáctenos para obtener información detallada sobre el precio y disponibilidad.
935106861
info@markelab.com
name
Adenosine Kinase (ADK) Antibody
category
Primary Antibodies
provider
Abbexa
reference
abx171082
tested applications
WB, IHC, IF/ICC
Description
This product is currently in development. The lead time for this product may be several months. Please contact us at
Documents del producto
Instrucciones
Data sheet
Product specifications
Category | Primary Antibodies |
Immunogen Target | Adenosine Kinase (ADK) |
Host | Mouse |
Reactivity | Human |
Recommended Dilution | WB: 0.01-2 µg/ml, IHC: 5-20 µg/ml, IF/ICC: 5-20 µg/ml. Optimal dilutions/concentrations should be determined by the end user. |
Clonality | Monoclonal |
Conjugation | Unconjugated |
Purification | Purified by Protein A and Protein G affinity chromatography. |
Size 1 | 1 ml |
Form | Liquid |
Tested Applications | WB, IHC, IF/ICC |
Buffer | 0.01 M PBS, pH 7.4, containing 0.05% Proclin-300, 50% glycerol. |
Availability | Please enquire. |
Storage | Aliquot and store at -20°C. Avoid repeated freeze/thaw cycles. |
Dry Ice | No |
Alias | AK |
Background | Antibody anti-ADK |
Status | RUO |
Descripción
Adenosine kinase (ADK) is a fundamental enzyme in purine metabolism that phosphorylates adenosine to produce adenosine monophosphate (AMP), thereby regulating intracellular adenosine concentrations. This activity is critical for maintaining energy balance, nucleotide synthesis, and the modulation of adenosine-dependent signaling pathways. Adenosine is a potent neuromodulator and anti-inflammatory molecule, and ADK indirectly controls its availability, affecting processes such as cellular stress responses, immune modulation, and neuronal excitability. Dysregulation of ADK has been implicated in epilepsy, ischemia, and cancer, as reduced adenosine levels exacerbate excitotoxicity, inflammation, and metabolic stress. In cancer, overexpression of ADK supports tumor metabolism by favoring nucleotide production. ADK inhibitors are under investigation as therapeutic agents for neurological disorders, where enhancing extracellular adenosine can exert protective effects against seizures and neurodegeneration. Expanding research into ADK highlights its role as a central regulator of energy metabolism and its potential as a therapeutic target for a variety of diseases.
Related Products

ADK antibody
ATP dependent phosphorylation of adenosine and other related nucleoside analogs to monophosphate derivatives. Serves as a potential regulator of concentrations of extracellular adenosine and intracellular adenine nucleotides.
Ver Producto
Recombinant Human ADK
Ver Producto